IL-23 monoclonal antibody treatment for Crohn's disease and ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 study enrolls adults diagnosed with moderate to severe Crohn's disease or ulcerative colitis according to Chinese guidelines and treats them with an IL-23 monoclonal antibody. Treatment is initiated and adjusted by physicians, with clinical visits and evaluations at weeks 0, 4, 8, 16, 24, 48, and 54. At those visits the study collects blood, stool, and tissue samples and performs endoscopy, imaging, laboratory tests, symptom self-assessments, adverse event monitoring, and nutritional risk screening. The protocol is focused on real-world safety and effectiveness data gathered during routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female subjects aged between 18 and 65 years at the baseline visit;
2. Patients diagnosed with CD and UC as per the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023 · Guangzhou) and the Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023 · Xi'an);
3. If the subject is a fertile female, a pregnancy test must be conducted at the baseline to rule out pregnancy. The entire trial process must follow the contraceptive recommendations of this project (see below); women without reproductive potential (defined as post-menopause or permanent surgical sterilization) do not need to undergo a pregnancy test at the baseline;
4. The subjects fully understand the purpose of the trial, and should have a basic understanding of the pharmacological effects of the trial drugs and the possible adverse reactions; in accordance with the spirit of the Helsinki Declaration, they voluntarily sign the informed consent form and comply with the requirements of this research protocol.

Exclusion Criteria:

1. Diagnosed with ischemic enteritis, infectious enteritis, radiation enteritis, NSAIDs-related enteritis, and other autoimmune enteropathies;
2. Unable to administer IL-23 inhibitors regularly by intravenous or subcutaneous injection;
3. Evidence of toxic megacolon was detected during screening;
4. Previously underwent small bowel resection, ileocecal resection, extensive colon resection, subtotal resection or total colon resection, rectal resection, ileostomy, colostomy;
5. Subjects who need surgery due to the condition or plan to undergo elective surgery during the study;
6. Complicated with severe liver and kidney dysfunction;
7. Complicated with active bacterial or viral infections, chronic infections;
8. Biologic agents are contraindicated such as active tuberculosis with positive chest X-ray or strongly positive tuberculin skin test, active tuberculosis within the past five years, myocardial infarction, heart failure or demyelinating neurological diseases;
9. Had severe opportunistic infections during screening, such as severe or recurrent herpes zoster, active cytomegalovirus infection, Pneumocystis jirovecii, Histoplasma capsulatum, etc. infections;
10. Have a history of gastrointestinal dysplasia, or any biopsy during endoscopic examination has revealed dysplasia, excluding completely resected low-grade dysplastic lesions; Patients with a known history of lymphoid tissue proliferative diseases (including lymphoma), or with signs and symptoms of lymphoid tissue proliferative diseases (such as lymphadenopathy and/or splenomegaly); Patients with current or past malignant tumors.

Where it's running

• The Sixth Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Jiayin Yao, Doctor
• Email: yjyin@mail2.sysu.edu.cn
• Phone: +8613826462890

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Renal Health in Adults with Inflammatory Bowel Disease and the General Population

  This study tests how common kidney problems are in adults with IBD compared with people without IBD.

  Recruiting Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji · Warsaw, Warszawa · NCT07593352

• Guselkumab for adults with Crohn's disease after ustekinumab failure

  This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07487480

• Registry for patients with Inflammatory Bowel Disease

  This study is creating a registry to gather information from people with Inflammatory Bowel Disease to help researchers learn more about the condition and find better treatments.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT04243525

• Bacillus probiotic spores to help treat Crohn's disease and ulcerative colitis

  This study tests whether adding multi-strain Bacillus spore probiotics to standard IBD treatment helps people with Crohn's disease or ulcerative colitis.

  Recruiting Anabio R&D · Hà Nội · NCT07799428

• A platform for collecting health data on ME/CFS and Long Covid

  This study is trying to collect health information from adults with ME/CFS and Long Covid to help researchers better understand these conditions and improve future treatments.

  Recruiting Brain Inflammation Collaborative · Delafield, Wisconsin · NCT04806620

• Familial IBD Early Risk

  This study tests whether clinical, environmental, and immune factors in first-degree relatives of people with Crohn’s disease or ulcerative colitis can predict who will develop IBD.

  Recruiting Seattle Children's Hospital · Seattle, Washington · NCT07791862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.